# Lactate transmission from hypoxic tumor cells promotes macrophage senescence and M2 polarization via the DNMT1-NHE7 axis to accelerate endometrial cancer progression

**Authors:** Shizhou Yang, Yuejiang Ma, Tingting Wu, Xiufeng Huang

PMC · DOI: 10.1038/s41419-026-08411-y · Cell Death & Disease · 2026-01-30

## TL;DR

This study shows how lactate from hypoxic tumor cells promotes cancer growth by causing macrophage changes through a specific molecular pathway.

## Contribution

The study identifies a novel DNMT1-NHE7 axis linking lactate transmission to macrophage senescence and M2 polarization in endometrial cancer.

## Key findings

- HIF1A drives lactate production in EC cells, which is transported to macrophages via MCT1.
- Lactate induces DNMT1 lactylation, leading to NHE7 downregulation and M2 macrophage polarization.
- NHE7 overexpression in macrophages reduces tumor growth and M2 polarization in xenograft models.

## Abstract

Although hypoxia is a well-known key driver of metabolic reprogramming in endometrial cancer (EC), its role in lactate-mediated macrophage activation remains unclear. This study investigates whether hypoxia-mediated lactate metabolism reprogramming facilitated EC progression via macrophages. Our data demonstrated that hypoxia-inducible factor 1 subunit alpha (HIF1A) drives a lactate-regulated metabolic cascade, elevating glycolytic genes and monocarboxylate transporter 3 (MCT3) in EC cells to produce and export more lactate. This lactate is transported to macrophages by MCT1 to drive M2 macrophage polarization. Mechanistically, lactate induces lactylation of Histone 3 in the promoter of DNA methyltransferase 1 (DNMT1) gene and activates transcription in macrophages, leading to the silencing of NHE7 gene expression, a key regulator of intracellular pH. Critically, NHE7 downregulation drives M2 polarization and senescence through the mitogen-activated protein kinase (MAPK) pathway activation in macrophages, ultimately facilitating EC progression. In vivo, we successfully established a xenograft tumor model using Ishikawa cells, and the data further confirmed that NHE7-overexpressing macrophages effectively abrogate exogenous lactate-accelerated xenograft tumor growth, as well as its M2 polarization and senescence. These findings uncover that hypoxia-mediated lactate production and transmission promote tumor-macrophage crosstalk via the DNMT1-NHE7 axis and EC progression, which offers novel therapeutic targets for EC.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123], CMA1 (chymase 1) [NCBI Gene 1215], DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786], SLC9A7 (solute carrier family 9 member A7) [NCBI Gene 84679]
- **Diseases:** endometrial cancer (MONDO:0002447)

## Full-text entities

- **Genes:** SLC9C1 (solute carrier family 9 member C1) [NCBI Gene 285335] {aka NHE, NHE-10, SLC9A10, sperm-NHE}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, HK2 (hexokinase 2) [NCBI Gene 3099] {aka HKII, HXK2}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, LCTL (lactase like) [NCBI Gene 197021] {aka KLG, KLPH}, SLC16A8 (solute carrier family 16 member 8) [NCBI Gene 23539] {aka MCT3, REMP}, ENO2 (enolase 2) [NCBI Gene 2026] {aka HEL-S-279, NSE}, ALDOB (aldolase, fructose-bisphosphate B) [NCBI Gene 229] {aka ALDB, ALDO2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, SLC9A7 (solute carrier family 9 member A7) [NCBI Gene 84679] {aka MRX108, NHE-7, NHE7}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, CD163 (CD163 molecule) [NCBI Gene 9332] {aka M130, MM130, SCARI1}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, SLC16A12 (solute carrier family 16 member 12) [NCBI Gene 387700] {aka CJMG, CRT2, CTRCT47, MCT12}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, PGK1 (phosphoglycerate kinase 1) [NCBI Gene 5230] {aka HEL-S-68p, MIG10, PGKA}, HBA2 (hemoglobin subunit alpha 2) [NCBI Gene 3040] {aka ECYT7, HBA-T2, HBH}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}, ALDOA (aldolase, fructose-bisphosphate A) [NCBI Gene 226] {aka ALDA, GSD12, HEL-S-87p}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, TEKT1 (tektin 1) [NCBI Gene 83659], GRIN2B (glutamate ionotropic receptor NMDA type subunit 2B) [NCBI Gene 2904] {aka DEE27, EIEE27, GluN2B, MRD6, NMDAR2B, NR2B}, SLC16A3 (solute carrier family 16 member 3) [NCBI Gene 9123] {aka MCT 3, MCT 4, MCT-3, MCT-4, MCT3, MCT4}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, SLC16A7 (solute carrier family 16 member 7) [NCBI Gene 9194] {aka MCT2}, GLB1 (galactosidase beta 1) [NCBI Gene 2720] {aka EBP, ELNR1, MPS4B}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}
- **Diseases:** Hypoxia (MESH:D000860), deaths (MESH:D003643), metastasis (MESH:D009362), metabolic syndrome (MESH:D024821), inflammation (MESH:D007249), tumorigenesis (MESH:D063646), EC (MESH:D016889), pancreatic ductal adenocarcinoma (MESH:D021441), aggressiveness (MESH:D010554), UMAP (MESH:C567162), macrophage dysfunction (MESH:D055501), fibrosis (MESH:D005355), Cancer (MESH:D009369), hepatocellular carcinoma (MESH:D006528), hypoxic (MESH:D002534), tumorigenic (MESH:D002471)
- **Chemicals:** 5-methylcytosine (MESH:D044503), O2 (MESH:D010100), 5-aza (MESH:D000077209), PVDF (MESH:C024865), proton (MESH:D011522), Triton X-100 (MESH:D017830), paraformaldehyde (MESH:C003043), penicillin (MESH:D010406), streptomycin (MESH:D013307), ethanol (MESH:D000431), DMSO (MESH:D004121), water (MESH:D014867), BCECF AM (MESH:C057433), Lipofectamine 2000 (MESH:C086724), PBS (MESH:D007854), OA (MESH:D010072), CO2 (MESH:D002245), paraffin (MESH:D010232), 25-hydroxycholesterol (MESH:C007997), Hematoxylin (MESH:D006416), crystal violet (MESH:D005840), 2-ME (MESH:D008623), methanol (MESH:D000432), DAPI (MESH:C007293), glucose (MESH:D005947), BCA (MESH:C047117), U0126 (MESH:C113580), PMA (MESH:D013755), lipid (MESH:D008055), Trizol (MESH:C411644), calcium (MESH:D002118), glutaraldehyde (MESH:D005976), formaldehyde (MESH:D005557), SDS (MESH:D012967), DEPC (MESH:D004047), puromycin (MESH:D011691), L-LA (MESH:D019344), xylene (MESH:D014992), C16-PAF (MESH:C037145), methionine (MESH:D008715), HY-12031A (-), X-gal (MESH:C044888), formazan (MESH:D005562), isopropanol (MESH:D019840), McCoy's 5 A medium (MESH:C113109)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Mycoplasma (genus) [taxon 2093]
- **Mutations:** W013032A, C +- 1  C
- **Cell lines:** YDT-0225 — Homo sapiens (Human), Angelman syndrome, Transformed cell line (CVCL_8V33), Ishikawa — Homo sapiens (Human), Type I endometrial adenocarcinoma, Cancer cell line (CVCL_2529), Lenti- — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A4EW), HEC-1-A — Homo sapiens (Human), Type II endometrial adenocarcinoma, Cancer cell line (CVCL_0293), YDT-0019 — Homo sapiens (Human), Transformed cell line (CVCL_K301), H-J — Homo sapiens (Human), Bladder carcinoma, Cancer cell line (CVCL_M891), YDT-0666 — Homo sapiens (Human), Transformed cell line (CVCL_9B30), EC — Homo sapiens (Human), Type II endometrial adenocarcinoma, Cancer cell line (CVCL_1274), M0 — Homo sapiens (Human), Familial hypertrophic cardiomyopathy type 26, Induced pluripotent stem cell (CVCL_A6XE), MIA PaCa-2 — Homo sapiens (Human), Pancreatic undifferentiated carcinoma, Cancer cell line (CVCL_0428), HEK-293T — Homo sapiens (Human), Transformed cell line (CVCL_0063), THP-1 — Homo sapiens (Human), Childhood acute monocytic leukemia, Cancer cell line (CVCL_0006)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12876988/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12876988/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12876988/full.md

---
Source: https://tomesphere.com/paper/PMC12876988